GlassScriptPhysician profile
Thomas B Richardson
NPI 1528099355
$3,885.53
in general payments reported to CMS, 2019-2025
17 companies · $541 in 2025
The $541 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $392 · 2021: $554 · 2022: $446 · 2023: $588 · 2024: $503 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $603.28 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $574.60 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $525.07 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $360.12 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $336.17 | 2020-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $241.76 | 2019-2021 | |
| Allergan, INC. | $227.02 | 2019-2020 | |
| Alkermes, INC. | $206.59 | 2019-2024 | Aristada, Lybalvi |
| Abbvie INC. | $204.36 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $195.25 | 2023-2025 | Uzedy, Austedo Xr |
| Lundbeck LLC | $116.73 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $86.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $80.78 | 2025 | Cobenfy |
| Amgen INC. | $41.06 | 2019 | |
| Indivior INC. | $36.58 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $32.68 | 2024-2025 | Loreev Xr |
| Corium, LLC | $16.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.